AI Medical Technology develops Dermalyser, an AI-driven, mobile decision support application that assists medical professionals in diagnosing skin cancer. Dermalyser is used with a dermatoscope mounted to a smartphone camera; clinicians take an image and receive an AI diagnosis within seconds. A prospective, multicentre, peer‑reviewed clinical trial published in the British Journal of Dermatology reported Dermalyser achieved 95% sensitivity and 86% specificity and outperformed primary care physicians and specialist dermatologists. The company will use the recently raised bridge financing to support ongoing regulatory efforts and further development of Dermalyser. Management says the roadmap is consolidated, with a significant Series A planned later this year and a target IPO in 2027–2028. The team is focused on bringing the clinically validated tool through trials and to market.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2024